• Geriatric assessment in adults age 50 years and older undergoing autologous hematopoietic cell transplantation for lymphoma. (ucsf.edu)
  • A randomized phase III trial of consolidation with autologous hematopoietic cell transplantation followed by maintenance rituximab vs. maintenance rituximab alone for patients with mantle cell lymphoma in minimal residual disease-negative first complete remission. (slu.edu)
  • Syed A. Abutalib, MD , of Cancer Treatment Centers of America, and Nelli Bejanyan, MD , of the University of Minnesota, discuss findings from a study conducted by the Center for International Blood and Marrow Transplant Research on treatment for ALL patients, with an available donor, undergoing myeloablative allogeneic hematopoietic cell transplantation in first complete remission (Abstract 684). (ascopost.com)
  • In an interview with OncLive , Pagel, chief of the Hematologic Malignancies Program, and director of the Hematopoietic Cell Transplantation Program, at Swedish Cancer Institute, discussed current treatment approaches in frontline and relapsed/refractory DLBCL and provided insight on some of the agents that are generating excitement in the relapsed/refractory setting. (onclive.com)
  • No prior autologous or allogeneic hematopoietic cell transplantation. (stanford.edu)
  • Historically, most cases of the intravascular lymphomas responded very poorly to standard chemotherapy regimens that were used to treat other types of the B-cell lymphomas. (wikipedia.org)
  • More recently, however, the addition to these chemotherapy regimens of the immunotherapy agents, Rituximab, which acts to kill B-cells, has greatly improved their effectiveness and thereby the prognosis of the most common form of these diseases, the intravascular B-cell lymphomas. (wikipedia.org)
  • Bulky symptomatic disease may require combination regimens, such as chemotherapy. (medscape.com)
  • [ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
  • Common combination regimens include: Rituximab with CVP regime (R-CVP), R-CHOP, R-Bendamustine. (lymphomaindia.com)
  • These are intensive chemotherapy regimens that, on one level, serve to identify patients who can tolerate such therapy, and they may offer potent cytoreduction, with the quality of remission being the biggest predictor of success with subsequent high-dose chemotherapy and autologous stem cell transplantation. (expertperspectives.com)
  • Check specific guidelines for restaging and dosage adjustments for chemotherapy and/or radiation therapy depending on positron-emission tomography (PET) scanning throughout the various regimens. (medscape.com)
  • Regimens that combine chemotherapy and radiation therapy (RT) have replaced RT alone for treatment of early-stage, favorable disease. (medscape.com)
  • Although combination chemotherapy regimens, including the nucleoside analogue fludarabine, were once the most commonly used first-line therapy in CLL, non-chemotherapy regimens (eg, with Bruton tyrosine kinase [BTK] inhibitors) are currently preferred in most cases. (medscape.com)
  • 17. Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma. (whocc.org.cn)
  • Burkitt lymphoma, or small noncleaved cell lymphoma, is a highly aggressive B-cell non-Hodgkin lymphoma (NHL) characterized by the translocation and deregulation of the c-myc gene on chromosome 8. (medscape.com)
  • Biopsy findings were consistent with small noncleaved cell non-Hodgkin lymphoma. (medscape.com)
  • Waldenström's macroglobulinemia is a slow-growing form of non-Hodgkin lymphoma that originates in white blood cells known as B lymphocytes. (sciencedaily.com)
  • Intravascular large B-cell lymphoma (IVBCL), which constitutes ~90% of all IVL, is a lymphoma of malignant B-cell lymphocytes as classified by the World Health Organization, 2016. (wikipedia.org)
  • these IVL are 1) intravascular NK-cell lymphoma (IVNKL) in which the malignant cells are a type of T cell lymphocyte termed natural killer cells (NK-cells) and 2) intravascular T-cell lymphoma (IVTL) in which the neoplastic cells are primarily, if not exclusively, a type of t-cell termed cytotoxic T-cells. (wikipedia.org)
  • By 2001, the World Health Organization had defined the disease as a malignant B-cell lymphoma termed intravascular large B-cell lymphoma. (wikipedia.org)
  • Some 2 dozen other cases of intravascular NK cell lymphoma have been reported by 2018. (wikipedia.org)
  • 3 - 5 This report by the Spanish Lymphoma Group (GELTAMO) aims to provide useful guidelines and recommendations for the prevention, diagnosis, and treatment of central nervous system diffuse large B-cell lymphoma patients with, or at risk of, leptomeningeal and/or brain parenchyma lymphoma relapse. (haematologica.org)
  • Several factors hinder the identification of risk factors for central nervous system (CNS) involvement in diffuse large B-cell lymphoma (DLBCL), including the retrospective nature of most studies, the relatively low frequency of CNS relapse in DLBCL, and the heterogeneity of CNS prophylaxis methods used in these studies. (haematologica.org)
  • Several studies 10 7 5 4 and a recent meta-analysis 1 have described a decrease in rates of CNS relapse in the post-rituximab era (probably due to improved control of systemic lymphoma), in addition to a change in the pattern of CNS relapse, with predominance of parenchymal over leptomeningeal relapse, isolated over combined (systemic plus CNS) relapses, and delayed CNS relapses. (haematologica.org)
  • Randomized phase II trial on primary chemotherapy with high-dose methotrexate and high-dose cytarabine with or without thiotepa, and with or without rituximab, followed by brain irradiation vs. high-dose chemotherapy supported by autologous stem cells transplantation for immunocompetent patients with newly diagnosed primary cns lymphoma. (clinicaltrialsregister.eu)
  • Mantle cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells localized in primary follicles or in the mantle region of secondary follicles. (medscape.com)
  • Mantle cell lymphoma (MCL) is recognized in the Revised European-American Lymphoma and World Health Organization classifications as a distinct clinicopathologic entity. (medscape.com)
  • it was frequently categorized as diffuse small-cleaved cell lymphoma (by the International Working Formulation) or centrocytic lymphoma (by the Kiel classification). (medscape.com)
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). (smw.ch)
  • Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. (smw.ch)
  • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (smw.ch)
  • High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)
  • High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
  • High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. (smw.ch)
  • The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
  • Diffuse large B-cell lymphoma (DLBCL) is the most common form of NHL, accounting for more than 30 percent of newly diagnosed cases. (lymphomaindia.com)
  • Another example is "primary mediastinal B-cell lymphoma" which often occurs in younger patients and grows rapidly in the chest (mediastinum) Often, the first sign of DLBCL is a painless rapid swelling in the neck, armpit, or groin, which is caused by enlarged lymph nodes. (lymphomaindia.com)
  • Follicular lymphoma (FL), a B-cell lymphoma, is the most common indolent (slow-growing) form of NHL, accounting for approximately 20 percent to 30 percent of all NHLs. (lymphomaindia.com)
  • Approximately 30-40 % of patients with FL will eventually transform to a more aggressive form of lymphoma like Diffuse Large B Cell Lymphoma and may require intensive chemotherapy followed by autologous stem cell transplantation. (lymphomaindia.com)
  • 57î 1% (12/21) of the patients showed diffuse large B cell lymphoma. (bvsalud.org)
  • 28.6% (6/21) of the patients showed anaplastic large cell lymphoma and 9.5% (2/21) of the patients showed T cell lymphoblastic lymphoma. (bvsalud.org)
  • CONCLUSION: Diffuse large B cell lymphoma is the most common pathological type of PBL. (bvsalud.org)
  • Treatment recommendations for patients with diffuse large B-cell lymphoma (DLBCL) begin with evaluating the extent of the disease, performance status of the patient, and histologic subtypes. (medscape.com)
  • A 58-year-old man had a relapsed follicular lymphoma (Grade 2) and was treated with mitoxantrone, fludarabine and dexamethasone followed by rituximab, and achieved partial remission. (elsevierpure.com)
  • Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease. (unicatt.it)
  • Safety, tolerability, toxicity management, and supportive care are important aspects of patient counseling in the treatment of diffuse large B-cell lymphoma (DLBCL). (expertperspectives.com)
  • The precise biological function of Interleukin-1 receptor 8 (IL-1R8) in diffuse large B-cell lymphoma (DLBCL) is still not well understood. (bvsalud.org)
  • PURPOSE: To investigate the prognosis value of a combined model based on 18F-fluoro-deoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) baseline and interim parameters in patients with diffuse large B-cell lymphoma (DLBCL). (bvsalud.org)
  • Serum Levels of the Chemokine CXCL13, Genetic Variation in CXCL13 and Its Receptor CXCR5, and HIV-Associated Non-Hodgkin B-Cell Lymphoma Risk. (medscape.com)
  • Rituximab (chimeric anti-CD20 monoclonal antibody) is widely employed in the treatment of patients with B cell non-Hodgkin lymphoma (NHL). (ashpublications.org)
  • CD20-directed monoclonal antibodies clearly demonstrate clinical efficacy in patients with B cell non-Hodgkin's lymphoma (NHL). (ashpublications.org)
  • 1 In diffuse large B cell lymphoma and in mantle cell lymphoma, response rates are in the 30% range. (ashpublications.org)
  • Malignant blast cells (i.e. diffuse large B-cell lymphoma) are fast-growing and result in aggressive disease, whereas malignant mature lymphocytes (i.e. follicular lymphoma) behave indolently. (oncolink.org)
  • Validation of the ΔSUV for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial. (canceropole-est.org)
  • Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial. (canceropole-est.org)
  • Non-Relapse Mortality after CAR T-Cell therapy for Large B-Cell Lymphoma: A LYSA Study from the DESCAR-T Registry. (canceropole-est.org)
  • Tandem haematopoietic stem cell transplantation versus single cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA. (canceropole-est.org)
  • Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and Rituximab. (canceropole-est.org)
  • Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study. (canceropole-est.org)
  • Patients with previously untreated mantle cell lymphoma received VcR-CVAD chemotherapy every 21 days for 6 cycles, followed by MR for 2 years. (elsevierpure.com)
  • VcR-CVAD produced highORRand CRrates in mantle cell lymphoma. (elsevierpure.com)
  • P. Connor Johnson, MD, and Jeremy S. Abramson MD, MMSc, discuss available treatments for patients with Burkitt lymphoma and high-grade B-cell lymphoma. (cancernetwork.com)
  • This article reviews the current data and future directions in the management of Burkitt lymphoma (BL) and high-grade B-cell lymphoma (HGBL). (cancernetwork.com)
  • BL is a rare, mature B-cell lymphoma molecularly defined by translocation of the proto-oncogene MYC. (cancernetwork.com)
  • HGBL, not otherwise specified (NOS) is a heterogeneous, aggressive, mature B-cell lymphoma that does not meet criteria for BL, DHL, or diffuse large B-cell lymphoma NOS. (cancernetwork.com)
  • 1 A significant minority of these cases were the especially aggressive B-cell lymphomas Burkitt lymphoma (BL) and high-grade B-cell lymphoma (HGBL), the latter of which includes the histologic subtypes HGBL with MYC and BCL2 and/or BCL6 translocations (conventionally referred to as double-hit lymphoma [DHL]) and HGBL, not otherwise specified (NOS). (cancernetwork.com)
  • To investigate effects of the preautografting administration of rituximab on the mobilization and engraftment of peripheral blood stem cells (PBSC), we retrospectively analyzed the outcomes of 43 newly diagnosed diffuse-large B-cell lymphoma patients who received CHOP chemotherapy with or without rituximab as a first-line treatment before autologous PBSC transplantation (PBSCT). (elsevierpure.com)
  • In an analysis reported in the Journal of Clinical Oncology , Fenske et al compared outcomes with early or late autologous vs reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in a population of patients with chemotherapy-sensitive mantle cell lymphoma. (ascopost.com)
  • The study involved analysis of data from 519 patients with chemotherapy-sensitive mantle cell lymphoma receiving transplantations between 1996 and 2007 who were reported to the Center for International Blood and Marrow Transplant Research. (ascopost.com)
  • The most common non-Hodgkin lymphoma diagnoses in children are Burkitt lymphoma, diffuse large B-cell lymphoma, lymphoblastic lymphoma, and anaplastic large cell lymphoma. (dana-farber.org)
  • These diseases include mycosis fungoides and subcutaneous panniculitis-like T-cell lymphoma. (dana-farber.org)
  • Primary central nervous system lymphoma in children is usually of the diffuse large B-cell lymphoma type. (dana-farber.org)
  • Treatment for primary central nervous system lymphoma requires high doses of chemotherapy that enter the central nervous system, such as high-dose methotrexate and high-dose cytarabine. (dana-farber.org)
  • Radiation therapy has been used as part of the treatment for this lymphoma in adults but may not be necessary if high dose chemotherapy is used in the treatment plan. (dana-farber.org)
  • Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. (ucsf.edu)
  • For the gene family, see B-cell CLL/lymphoma . (wikipedia.org)
  • [9] If enlarged lymph nodes are caused by infiltrating CLL-type cells, a diagnosis of small lymphocytic lymphoma (SLL) is made. (wikipedia.org)
  • ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. (viictr.org)
  • Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma, which is a form of cancer that affects the lymphatic system. (rarediseases.org)
  • MCL is a B-cell lymphoma that develops from malignant B-lymphocytes within a region of the lymph node known as the mantle zone. (rarediseases.org)
  • Mantle cell lymphoma belongs to a group of diseases known as non-Hodgkin's lymphomas, which are related malignancies (cancers) that affect the lymphatic system. (rarediseases.org)
  • The value of CD23 expression as an additional marker in distinguishing mediastinal (thymic) large B-cell lymphoma from Hodgkin lymphoma. (pharmateca.ru)
  • Primary mediastinal large B-cell lymphoma. (pharmateca.ru)
  • Non-Hodgkin's lymphoma is classified based on the specific type of lymphocyte involved and the characteristics of the cancer cells. (cims.org)
  • Diffuse Large B-Cell Lymphoma (DLBCL): The most common subtype, characterized by rapidly growing tumors in the lymph nodes. (cims.org)
  • Follicular Lymphoma: Slow-growing cancer that originates in the B-cells and primarily affects the lymph nodes. (cims.org)
  • Mantle Cell Lymphoma: Usually diagnosed at an advanced stage, this subtype involves the lymph nodes, spleen, and bone marrow. (cims.org)
  • Blood Tests: These tests can help evaluate blood cell counts, identify specific markers related to lymphoma, and assess overall health. (cims.org)
  • Umberto Vitolo, MD , of Città della Salute e della Scienza Hospital and University, and Sagar Lonial, MD , of Emory University, discuss study findings on obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (Abstract 470). (ascopost.com)
  • Steven Le Gouill, MD, PhD , of Nantes University Hospital and INSERM, discusses in French study findings from the Lysa/Goelams Group on rituximab maintenance after autologous stem cell transplantation in younger patients with mantle cell lymphoma (Abstract 145). (ascopost.com)
  • In diffuse large B-cell lymphoma (DLBCL), it's critical to understand the genetic risk of each individual patient, according to John M. Pagel, MD, PhD, who added that genetic risk can inform up-front and newly expanding options in the relapsed/refractory setting. (onclive.com)
  • On July 31, 2020, the FDA approved tafasitamab in combination with lenalidomide (Revlimid) for patients with relapsed/refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant. (onclive.com)
  • DLBCL has been, largely, a success story for us over the past years because we are now able to provide cures to at least 60% of patients with large cell lymphoma. (onclive.com)
  • The type of lymphoma] depends on the cell of origin. (onclive.com)
  • It's important to understand if it's a germinal center or non-germinal center large cell lymphoma because it's important for prognosis and may be important for treatment and survival. (onclive.com)
  • Now, molecular studies are looking at large cell lymphomas that really break them down into multiple different groups, perhaps 5 different types of large cell lymphoma, based on their genetic signature. (onclive.com)
  • If we see those, [we know] that this is usually a very aggressive large cell lymphoma. (onclive.com)
  • Background The aggressive form of Mantle cell non-hodgkin B cell lymphoma (MCL) has a dismal prognosis. (bmj.com)
  • Conclusions This case suggests that haplo-CAR T cell therapy can be effective in controlling lymphoma that failed to respond to autologous CAR T cell therapy and overcome limitation of autologous CAR T cells, thus may be one possible regimen before the era of off-the-shelf "universal" CAR T cell therapy. (bmj.com)
  • Mantle cell lymphoma (MCL) is a type of non-Hodgkin B cell lymphoma with a distinctive molecular marker cyclin D1 that is constitutively overexpressed in almost all cases. (bmj.com)
  • It is indicated to treat and manage multiple myeloma and mantle cell lymphoma. (magicinepharma.com)
  • Mantle Cell Lymphoma (MCL), whose tumor has relapsed or progressed after two prior treatments, one of which included therapy with Bortezomib. (magicinepharma.com)
  • Follicular Lymphoma (FL), as a component of combination therapy with a Rituximab product. (magicinepharma.com)
  • This is followed with non-myeloablative transplant using stem cells from a related or unrelated donor to try and generate an anti-lymphoma response from the new immune system. (stanford.edu)
  • Rituximab, bortezomib, modified hyper-cyclophosphamide, doxorubicin, vincristine, dexamethasone (VcR-CVAD) induction chemoimmunotherapy and maintenance rituximab (MR) were evaluated for efficacy and safety in Eastern Cooperative Oncology Group protocol E1405. (elsevierpure.com)
  • [12] The medications fludarabine , cyclophosphamide , and rituximab were previously the initial treatment in those who are otherwise healthy. (wikipedia.org)
  • Most important aspect of therapy is anti CD20 antibody, the Rituximab, which is a kind of immunotherapy or targeted therapy and attacks the CD20 antigen on the cancer cells. (lymphomaindia.com)
  • Multiagent chemotherapy + immunotherapy should be reserved for patients who are having advanced stages of disease and having symptoms/ difficulties related to it. (lymphomaindia.com)
  • These are slow growing tumors that may be treated with surgery, radiation therapy , the immunotherapy drug rituximab, or occasionally with antibiotics. (dana-farber.org)
  • [10] In those with significant symptoms, chemotherapy , immunotherapy , or chemoimmunotherapy may be used. (wikipedia.org)
  • Advances in cellular immunotherapy that spur genetically modified T cells to attack cancer cells have revolutionized the treatment of certain blood cancers. (wustl.edu)
  • The first-line treatment typically includes chemotherapy combined with immunotherapy, which is a combination of medications that destroy the cancer cells. (rarediseases.org)
  • Following that, patients may be eligible for a stem cell transplant, and/or an extended course of immunotherapy that is meant to prolong cancer remission. (rarediseases.org)
  • TROPION-Lung04: Phase 1b, multicenter study of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy ± carboplatin in advanced/metastatic non-small cell lung cancer (mNSCLC). (newsqwe.com)
  • Influence of systemic rituximab treatment on the incidence of CNS relapse in DLBCL and risk factors for CNS disease. (haematologica.org)
  • A study by Salles et al determined that correlations between specific biomarkers and the international prognostic index (IPI) score demonstrate that IPI remains the best available index in patients with DLBCL treated with rituximab and chemotherapy. (medscape.com)
  • 0.05) in DLBCL cells via CCK8 and apoptotic assays. (bvsalud.org)
  • Subsequent chemotaxis analysis indicated that natural killer (NK) cell recruitment could be suppressed by IL-1R8 signaling in DLBCL, at least partially through CXCL1 inhibition (p (bvsalud.org)
  • In line with this observation, elevated levels of NK cell infiltration demonstrated a significant positive correlation with improved overall survival (OS) among patients diagnosed with DLBCL (p (bvsalud.org)
  • Our data suggests the immuno-regulating potential of IL-1R8 through NK cell recruitment in DLBCL, providing novel insights into future immuno-modulating therapies. (bvsalud.org)
  • Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study. (canceropole-est.org)
  • The addition of rituximab (Rituxan) to standard CHOP-based chemotherapy represented a major advance in the frontline treatment of patients with DLBCL. (onclive.com)
  • MCL can be both indolent or aggressive, in either case it responds poorly to chemotherapy and consequently the aggressive form has a dismal prognosis assessed by incorporating Ki-67 proliferation index and Mantle Cell International Prognostic Index scores. (bmj.com)
  • High-dose chemotherapy and autologous stem cell transplantation (HCT-ASCT) after high-dose methotrexate (MTX)-based immuno-chemotherapy has become an increasingly used treatment approach in eligible elderly PCNSL patients with promising feasibility and efficacy, but has not been compared with conventional chemotherapy approaches. (biomedcentral.com)
  • A randomized controlled trial, incorporating a GA and comparing age-adapted HCT-ASCT treatment with conventional chemotherapy is needed. (biomedcentral.com)
  • The primary objective is to demonstrate that intensified chemotherapy followed by consolidating HCT-ASCT is superior to conventional chemotherapy with rituximab, MTX, procarbazine (R-MP) followed by maintenance with procarbazine in terms of progression free survival (PFS). (biomedcentral.com)
  • Treatment selection takes into account patient age, fitness, and whether autologous stem cell transplantation (ASCT) is planned. (medscape.com)
  • All the patients received chemotherapy (CHOP or CHOP like regimen, 33.3% plus rituximab) with or without radiotherapy and/or autologous hematopoietic stem cell transplantation (ASCT). (bvsalud.org)
  • Chemotherapy is the main treatment, which can be combined with radiotherapy and/or ASCT. (bvsalud.org)
  • Transplant-eligible patients had the option of autologous stem cell transplantation (ASCT) consolidation instead of MR. The primary end point was the complete response (CR) rate to VcR-CVAD. (elsevierpure.com)
  • Because of their similarities and extreme rarities, IVL lymphomas caused by NK-cells and cytotoxic T-cells are often grouped together under the term intravascular NK/T cell lymphomas (IVNK/TL). (wikipedia.org)
  • The malignant cells in IVNK/TL are typically infected with the Epstein-Barr virus suggesting that these lymphomas are examples of the Epstein-Barr virus-associated lymphoproliferative diseases. (wikipedia.org)
  • Intravascular large B-cell and intravascular NK/T cell IVL are typically very aggressive lymphomas that afflict middle-aged and elderly adults. (wikipedia.org)
  • Unfortunately, no such agent that is directed against NK-cells or cytotoxic T-cells has yet been reported to be useful in treating these two types of the intravascular B-cell lymphomas. (wikipedia.org)
  • Intravascular large B-cell lymphomas fall into three distinct variants, all of which involve the intravascular accumulation of malignant B-cells and appear to have a similar pathophysiology. (wikipedia.org)
  • The EC granted Cell Therapeutics' Pixuvri® (pixantrone) conditional marketing authorization for use as monotherapy in the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). (genengnews.com)
  • The belief that T-cell lymphomas have a worse prognosis than B-cell lymphomas remains controversial. (oncolink.org)
  • REAL/WHO- [6] - classification includes leukemias and lymphomas, with 3 categories based on lineage and morphology (Hodgkin, B cell, and T/NK cell). (oncolink.org)
  • The aggressive B-cell lymphomas BL, DHL, and HGBL, NOS are unique diseases with specific pathogenesis and biology. (cancernetwork.com)
  • However, there are several slow growing B-cell lymphomas that occur in this young age group. (dana-farber.org)
  • There are also rare T-cell lymphomas that are more frequently seen in adults but occasionally occur in children. (dana-farber.org)
  • Lymphomas are cancers that involve white blood cells, and can be divided depending on the type of cell involved, either B-lymphocytes or T-lymphocytes. (rarediseases.org)
  • MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. (pharmateca.ru)
  • B-Cell Lymphomas: Arise from abnormal B-lymphocytes, a type of white blood cell responsible for producing antibodies. (cims.org)
  • T-Cell Lymphomas: Originate from abnormal T-lymphocytes, a type of white blood cell that plays a role in cell-mediated immunity. (cims.org)
  • If you're seeing these very aggressive, large cell lymphomas, follow them very closely and be prepared for the next type of treatment they may need. (onclive.com)
  • 15. Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent. (whocc.org.cn)
  • The primary objectives of this study are to compare the efficacy of magrolimab + venetoclax + azacitidine versus placebo + venetoclax + azacitidine in participants with previously untreated acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. (slu.edu)
  • The chimeric anti-CD20 antibody rituximab was first studied in recurrent indolent NHL, and the "standard" regimen of 4 doses administered weekly (375 mg/m 2 ) resulted in an objective response rate of 48% with a median time to progression (TTP) of just over 1 year. (ashpublications.org)
  • This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma. (stanford.edu)
  • Although there isn't a cure for Waldenström's, treatments include drugs such as rituximab, bortezamib, and bendamustine. (sciencedaily.com)
  • He remains in complete remission 2 years after transplantation. (elsevierpure.com)
  • The early transplantation cohort was defined as patients in first partial or complete remission with no more than two lines of chemotherapy. (ascopost.com)
  • Among autologous transplantation recipients, 5-year overall survival was 75% in patients with first complete response with one line of pretransplantation therapy, 70% in those with first complete response with two lines of therapy, and 38% in those with primary induction failure-sensitive disease (partial remission with no history of complete response). (ascopost.com)
  • [ 6 ] Ibrutinib has demonstrated efficacy as monotherapy for rituximab-resistant cases, especially those with mutations in the MYD88 gene. (medscape.com)
  • it showed superior progression-free and overall survival with ibrutinib-rituximab compared with FCR, in particular in patients without the IGHV mutation, and lower rates of serious infectious complications with ibrutinib-rituximab. (medscape.com)
  • Most recently, dose-adjusted rituximab with EPOCH (R-EPOCH) chemoimmunotherapy. (onclive.com)
  • Strategies to potentially improve efficacy include increases in dose (particularly through "maintenance" or "extended induction" schedules), as well as the addition of chemotherapy or novel biologic agents. (ashpublications.org)
  • Evidence has suggested that prolonged exposure (beyond 4 weekly infusions) may improve efficacy of single agent rituximab therapy (as discussed fully by Dr. Ghielmini in this volume). (ashpublications.org)
  • The clinical manifestations of Waldenström macroglobulinemia result from the presence of the IgM paraprotein and malignant lymphoplasmacytic cell infiltration of the bone marrow and other tissue sites. (medscape.com)
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
  • Under terms of the conditional marketing approval, Cell Therapeutics will complete a post-marketing study to confirm the clinical benefits of Pixuvri. (genengnews.com)
  • PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-line Treatment of Subjects With A Phase 3 Clinical Trial Comparing Infusional 5 Fluorouracil, Leucovorin, and Oxaliplatin. (med-abstracts.com)
  • Scientists working in basic, translational, and clinical cancer metabolism research are invited to join the Academy in New York on April 17th to discuss the intersection between cell signaling and metabolism. (nyas.org)
  • The FORESEE Study is a multi-center, prospective clinical trial enrolling patients with Breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM). (stanford.edu)
  • We have a series of clinical trials available to evaluate several different strategies to prevent GVHD, such as T cell depletion and the use of novel immunosuppressive agents. (harvard.edu)
  • Clinical scientists continue to observe superior survival of patients treated with combined chemotherapy and radiation approaches, yet the mechanisms behind this synergistic therapeutic approach are not fully understood. (mdanderson.org)
  • The EMA's Committee for Medicinal Products for Human Use will also accept for review data from an ongoing Phase III trial, PIX306, which is comparing Pixuvri-rituximab to gemcitabine-rituximab in relapsed patients with aggressive B-cell NHL who aren't eligible for autologous stem cell transplantation. (genengnews.com)
  • When abnormal B cells begin to multiply out of control, they produce excessive amounts of a protein called monoclonal immunoglobulin, which causes the blood to thicken and flow less smoothly. (sciencedaily.com)
  • [18] CLLs are, in virtually all cases, preceded by a particular subtype of monoclonal B-cell lymphocytosis (MBL). (wikipedia.org)
  • Radioimmunotherapy (RIT) alone or in combination with chemotherapy: Two radioimmunotherapy drugs are commercially available: Iodine 131 tositumomab (Bexxar) and Y90 ibritumomab tiuxetan (Zevalin). (lymphomaindia.com)
  • This agent has activity in both indolent and aggressive disease, alone and in combination with chemotherapy. (ashpublications.org)
  • Defibrotide: Real World Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Stem Cell Transplant. (harvard.edu)
  • The nature of disease (indolent vs. aggressive) is correlated to the stage of lymphocytic differentiation of the malignant cells. (oncolink.org)
  • Case presentation Here, we report a case of a refractory MCL in a patient who had relapsed after conventional chemotherapy and autologous CAR T cell therapy. (bmj.com)
  • The mutation causes the cells to produce a distorted protein, which switches on the IRAK complex pathway, leading to activation of NF-kB, a protein that is essential for the growth and survival of Waldenström's tumor cells," Treon comments. (sciencedaily.com)
  • Larger studies are required to determine the impact of rituximab on the mobilization and function of PBSC as well as whether a survival advantage exists in patients who undergo auto-PBSCT with rituximab. (elsevierpure.com)
  • Early initiation of chemotherapy has failed to show survival benefit in CLL. (medscape.com)
  • There were no significant differences in 5-year overall survival for autologous vs reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in the early transplantation cohort or in the late cohort. (ascopost.com)
  • Survival was significantly better for both procedures when transplantation occurred earlier in the disease course. (ascopost.com)
  • Five-year overall survival was similar for the autologous vs the allogeneic transplantation groups in the early cohort (61% vs 62%, P = .951) and in the late cohort (44% vs 31%, P = .202). (ascopost.com)
  • Survival was significantly better in patients in the early cohort among both autologous ( P = .004) and allogeneic transplantation patients ( P = .005). (ascopost.com)
  • On multivariate analysis of overall survival from the time of diagnosis, stem cell transplantation beyond first complete response, greater age (≥ 60 years), no rituximab prior to transplantation, and increased lactate dehydrogenase at diagnosis were associated with significantly inferior survival. (ascopost.com)
  • In the autologous transplantation group, survival was greater with early vs late transplantation (relative risk [RR] of death = 0.70, P = .037). (ascopost.com)
  • Survival outcomes in patients with muscle-invasive bladder cancer receiving neoadjuvant chemotherapy stratified by number of cycles. (newsqwe.com)
  • A study by Pasricha et al found that bone marrow features, particularly the degree of plasma cell infiltration, correlates with IgM paraprotein concentration at diagnosis. (medscape.com)
  • Thus, evaluation of the plasma cell compartment in the bone marrow at baseline and after therapy may be helpful. (medscape.com)
  • Jalali et al reported that levels of soluble programmed cell death protein 1 (PD-1) ligands are elevated in patients with Waldenström macroglobulinemia and, in addition to surface-bound ligands in bone marrow, could regulate T-cell function. (medscape.com)
  • The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. (smw.ch)
  • Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. (smw.ch)
  • High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich. (smw.ch)
  • Leukemia is a group of clonal diseases derived from a single cell with a genetic alteration in bone marrow or peripheral lymphoid tissue, and each type is determined by the specificity of the source cell. (sld.cu)
  • Bone Marrow Transplantation , 39 (9), 523-527. (elsevierpure.com)
  • Chronic lymphocytic leukemia ( CLL ) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell ). (wikipedia.org)
  • [4] [9] CLL results in the buildup of B cell lymphocytes in the bone marrow, lymph nodes, and blood . (wikipedia.org)
  • [17] Less commonly, the disease comes to light only after the cancerous cells overwhelm the bone marrow, resulting in low red blood cells, neutrophils, or platelets. (wikipedia.org)
  • [18] Whereas, with CLL, diseased cells propagate from within the bone marrow, in SLL they propagate from within the lymphatic tissue. (wikipedia.org)
  • A study to evaluate stem cell collection times for patients seen at the Outpatient Bone Marrow Transplant Center at SSM Health Saint Louis University Hospital. (slu.edu)
  • Lymphatic tissues also include the thymus, a relatively small organ behind the breastbone that is thought to play an important role in the immune system until puberty, as well as the bone marrow, which is the spongy tissue inside the cavities of bones that manufactures blood cells. (rarediseases.org)
  • Similarly, recently published British guidelines 11 have concluded that the incidence of CNS relapse decreased after the introduction of rituximab ( Table 1 ). (haematologica.org)
  • Some patients may not respond to chemotherapy at all while few patients respond initially but later on relapse. (lymphomaindia.com)
  • The discovery was made by sequencing the genome of tumor cells in Waldenström's patients, reading the cells' DNA letter by letter, and seeing where it differed from that of the patients' normal cells. (sciencedaily.com)
  • We found that tumor cells in 90 percent of the patients we tested contained a single point mutation, an error in one of the bases that make up the 'rungs' of the DNA helix," says Steven Treon, MD, PhD, who led the research with his Dana-Farber colleague Zachary Hunter. (sciencedaily.com)
  • In subsequent experiments, when we treated the tumor cells with drugs that target the pathway activated by the mutated gene, the cells underwent apoptosis, or programmed cell death. (sciencedaily.com)
  • These results suggest that new, effective treatments that target the tumor cells directly are now possible for people with the disease. (sciencedaily.com)
  • For the current research, Treon and his colleagues conducted whole genome sequencing of tumor cells and normal cells from 30 patients with Waldenström's. (sciencedaily.com)
  • In collaboration with Complete Genomics of Mountain View, Calif., researchers "lined up" the sequences of the tumor and non-tumor cells to identify differences. (sciencedaily.com)
  • Ninety percent of the tumor cells had a point mutation in the gene MYD88. (sciencedaily.com)
  • When we shut down the pathway by blocking the abnormal protein with drug molecules, the tumor cells entered apoptosis. (sciencedaily.com)
  • Agents in this class halt the cell cycle at the G1 phase in tumor cells. (medscape.com)
  • CNSide can detect and quantify tumor cells in the CSF from patients with Breast Cancer or NSCLC having a suspicious or confirmed LM. (stanford.edu)
  • It inhibits cell proliferation by inducing apoptosis of tumor cells. (magicinepharma.com)
  • Such treatments now include CAR T-cell therapy, polatuzumab vedotin (Polivy), tafasitamab-cxix (Monjuvi) and selinexor. (onclive.com)
  • B and T lymphocytes, CD4+ B lymphocytes versus CD8+ T lymphocytes), and tests that measure T-cell proliferation or function in response to specific or nonspecific stimuli (e.g., lymphocyte proliferation assays) ( 4,5 ). (cdc.gov)
  • I have expertise in novel therapies for acute myeloid leukemia, stem cell mobilization and homing, as well as stem cell transplantation. (rochester.edu)
  • Although B-cells were completely depleted from PBSC in the rituximab group, we found no difference in the expression of CXCR-4, VLA-4 and c-Kit on PBSC, indicating that rituximab did not affect the expression of these adhesion molecules, which might be involved in the mechanism of mobilization. (elsevierpure.com)
  • These results indicated no adverse effect of rituximab on the mobilization and engraftment of PBSC. (elsevierpure.com)
  • Just-in-Time: Evaluating a Decision-based Algorithm for Plerixafor Usage in Stem Cell Mobilization in an Outpatient Transplant Center. (slu.edu)
  • In symptomatic patients, monotherapy with rituximab is the usual choice, especially for nonbulky disease. (medscape.com)
  • The Dana-Farber/Boston Children's Stem Cell Transplant Center offers autologous and allogeneic stem cell transplants and is active in researching new stem cell techniques. (dana-farber.org)
  • 9. Synchronous hairy cell leukemia and chronic lymphocytic leukemia: a case report with a brief review of literature. (whocc.org.cn)